- Title: Subtitle
- POSTER: IBCL-1072: Long-Term Follow-Up From the Rituximab Era Describes a Substantial “One-and-Done” Population After Frontline Treatment for Follicular Lymphoma
- Creators
- Jonathan Day - Mayo Clinic in ArizonaMelissa Larson - Mayo Clinic in ArizonaEric Mou - University of IowaUrshila Durani - Mayo Clinic in ArizonaCarla Casulo - University of RochesterMazie Tsang - Mayo Clinic in ArizonaUmar Farooq - University of IowaPatrizia Mondello - Mayo Clinic in ArizonaJC Villasboas Bisneto - Mayo Clinic in ArizonaCarrie Thompson - Mayo Clinic in ArizonaSergei Syrbu - University of IowaAndrew Feldman - Mayo Clinic in ArizonaChristopher Flowers - The University of Texas MD Anderson Cancer CenterStephen Ansell - Mayo Clinic in ArizonaThomas Witzig - Mayo Clinic in ArizonaThomas Habermann - Mayo Clinic in ArizonaJames Cerhan - Mayo Clinic in ArizonaBrian Link - Mayo Clinic in ArizonaYucai Wang - Mayo Clinic in ArizonaMatthew Maurer - Mayo Clinic in Arizona
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.26(Suppl 1), pp.S319-S319
- DOI
- 10.1016/S2152-2650(26)01203-6
- ISSN
- 2152-2650
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 08/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Pathology; Internal Medicine
- Record Identifier
- 9985222745802771
Abstract
POSTER: IBCL-1072: Long-Term Follow-Up From the Rituximab Era Describes a Substantial “One-and-Done” Population After Frontline Treatment for Follicular Lymphoma
Clinical lymphoma, myeloma and leukemia, Vol.26(Suppl 1), pp.S319-S319
08/2026
DOI: 10.1016/S2152-2650(26)01203-6
Details
Metrics
1 Record Views